Table 1.
Demographic, clinicopathologic, and texture features of the study population (N=198)
| Value | |
|---|---|
| Male sex, n (%) | 118 (60) |
| Age, years (range) | 61 (30–88) |
| Major comorbidity, n (%) | 110 (56) |
| Body mass index, kg/m2 (range) | 26.8 (17.2–44.3) |
| Node-positive primary tumor, n (%) | 69 (35) |
| Synchronous CRLM, n (%) | 112 (57) |
| Multiple metastases, n (%) | 114 (58) |
| CRS (score 0–2), n (%) | 118 (60) |
| CEA >200, n (%) | 3 (1.5) |
| Maximal tumor size, cm, mean ± SD | 3.5 ± 2.6 |
| Bilobar disease, n (%) | 86 (43) |
| Extrahepatic disease, n (%) | 17 (9) |
| Neoadjuvant chemotherapy, n (%) | 122 (62) |
| Preoperative PVE, n (%) | 23 (12) |
| Pathology of nontumoral liver, n (%) | |
| Steatosis | 68 (34) |
| Sinusoidal dilation | 26 (13) |
| Steatohepatitis (grade ≥4) | 7 (4) |
| Pathology of index tumor | |
| Total response >75%, n (%) | 38 (19) |
| Tumor fibrosis >40%, n (%) | 24 (12) |
| Percentage necrosis, median (range) | 30 (0–90) |
| Percentage fibrosis, median (range) | 10 (0–100) |
| Percentage mucin, median (range) | 0 (0–100) |
| Texture features, mean ± SD | |
| FLR correlation | 0.028 ± 0.025 |
| FLR homogeneity | 0.719 ± 0.064 |
| FLR contrast | 0.895 ± 0.375 |
| FLR energy | 0.239 ± 0.133 |
| FLR entropy | 0.469 ± 0.157 |
| Tumor correlation | 0.274 ± 0.156 |
| Tumor homogeneity | 0.629 ± 0.077 |
| Tumor contrast | 1.780 ± 0.843 |
| Tumor energy | 0.111 ± 0.088 |
| Tumor entropy | 0.052 ± 0.065 |
CRLM colorectal liver metastases, CRS clinical risk score, CEA carcinoembryonic antigen, PVE portal vein embolization, FLR future liver remnant